Profiling the oral microbiomes in patients with Alzheimer's disease
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Guo H, Li B, Yao H, Liu D, Chen R, Zhou S, Ji Y, Zeng L, Du M
Journal
Oral diseases
Year
2023
Keywords:
Alzheimer's disease, oral microbiomes, periodontal bacteria, periodontal disease
OBJECTIVES: To analyse the characteristics of the oral microbiomes and expected to find biomarkers about Alzheimer's disease (AD). SUBJECTS AND METHODS: AD patients (n = 26) and cognitive intact people (n = 26) were examined for cognition, depression, oral health and collected saliva and gingival crevicular fluid (GCF) in the morning. Full-length 16S rRNA gene was amplified and sequencing was performed using the PacBio platform. RESULTS: The predominant bacterium of salivary microbiome and periodontal microbiome from AD patients was Streptococcus oralis and Porphyromonas gingivalis, respectively. With respect to β diversity analysis, there was a significance difference in periodontal microbiome between AD patients and cognitively intact subjects. The relative abundance of Veillonella parvula significantly increased in oral microbiomes from AD patients. Interestingly, the dominant species were different between early-onset AD and late-onset AD patients. Moreover, the predominant species were changed as the clinical severity of AD. Furthermore, the correlation analysis revealed that V. parvula was associated with AD in both saliva and GCF and that P. gingivalis was associated with AD only in GCF. CONCLUSIONS: In this study, the microbiome community of oral microbes was altered in AD patients and periodontal microbiome was sensitive to cognition changes. Moreover, V. parvula and P. gingivalis were associated with AD.
Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- SalivaSaliva
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Alzheimer's diseaseAlzheimer's disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Cognitive intact subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Alzheimer's Disease (AD) patients
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with Alzheimer's Disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 26
- Group 1 sample size Number of subjects in the case (exposed) group
- 26
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- PacBio RS
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Metastats
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Experiment 5
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Early-onset Alzheimer's Disease patients (EAS)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Late-onset Alzheimer's Disease patients (NAS)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with late-onset Alzheimer's Disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 10
- Group 1 sample size Number of subjects in the case (exposed) group
- 16
Signature 1
Source: Figure 5a
Description: Differential bacteria in AD patients with different clinical types
Abundance in Group 1: increased abundance in Late-onset Alzheimer's Disease patients (NAS)
| NCBI | Quality Control | Links |
|---|---|---|
| Parvimonas micra | ||
| Prevotella veroralis | ||
| Segatella oris | ||
| Streptococcus anginosus | ||
| Veillonella parvula | ||
| Ligilactobacillus salivarius |
Signature 2
Source: Figure 5a
Description: Differential bacteria in AD patients with different clinical types
Abundance in Group 1: decreased abundance in Late-onset Alzheimer's Disease patients (NAS)
| NCBI | Quality Control | Links |
|---|---|---|
| Capnocytophaga leadbetteri | ||
| Streptococcus cristatus | ||
| Capnocytophaga granulosa | ||
| Neisseria elongata | ||
| Stomatobaculum longum |
Experiment 9
Differences from previous experiment shown
Subjects
Signature 2
Source: Figure S3d
Description: Differential abundance of bacteria in AD patients with different clinical types
Abundance in Group 1: decreased abundance in Late-onset Alzheimer's Disease patients (NAS)
Retrieved from "https://bugsigdb.org/w/index.php?title=34931394&oldid=154024"
